PARP-1活性(PAR)决定宫颈癌对奥拉帕尼的敏感性
该临床前研究在9株宫颈癌原代细胞系及异种移植瘤中评估奥拉帕尼活性。3株(33.3%)细胞系PAR化活性强,对奥拉帕尼体外敏感(IC50<2μM,p=0.0012);奥拉帕尼通过G2/M期阻滞和凋亡抑制生长,体内抑制肿瘤生长(p=0.0017)并延长动物总生存(p=0.008)。高水平PAR化与奥拉帕尼活性相关,可能作为识别获益患者的生物标志物。
要点
- 3/9(33.3%)宫颈癌原代细胞系PAR化活性强,对奥拉帕尼体外敏感(IC50<2μM,p=0.0012)。
- 奥拉帕尼通过G2/M期阻滞和凋亡抑制宫颈癌细胞生长(p<0.0001),涉及PARP酶抑制和捕获。
- 体内奥拉帕尼显著抑制宫颈癌异种移植瘤生长(p=0.0017)并提高动物总生存(p=0.008)。
核心结论
- 一部分宫颈癌原代细胞系在体外和体内对奥拉帕尼治疗高度敏感。
- 高水平PAR化与奥拉帕尼临床前活性相关,可能代表识别最受益于PARP抑制剂(PARPi)的宫颈癌患者的生物标志物。
研究设计与样本
- 临床前体外和体内研究,采用9株经全外显子测序(WES)的宫颈癌原代细胞系及宫颈癌异种移植瘤模型。
主要发现
- 9株原代宫颈癌细胞系中无1株显示同源重组缺陷(HRD)。
- 3/9(33.3%)原代宫颈癌细胞系显示强PAR化活性,对奥拉帕尼体外敏感(cutoff IC50值<2μM,p=0.0012)。
- 奥拉帕尼通过G2/M期细胞周期阻滞和诱导凋亡抑制宫颈癌细胞生长(p<0.0001)。
- 奥拉帕尼在宫颈癌中的活性涉及PARP酶抑制和PARP捕获。
- 体内奥拉帕尼显著削弱宫颈癌异种移植瘤生长(p=0.0017)并提高动物总生存(p=0.008)。
关键数值与推荐
- 高PAR化活性(3/9株,33.3%)与奥拉帕尼体外敏感性相关(cutoff IC50值<2μM,p=0.0012)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cervical cancer (CC) remains a major health problem worldwide. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors (PARPi) have emerged as a promising class of chemotherapeutics in ovarian cancer. We explored the preclinical in vitro and in vivo activity of olaparib against multiple primary whole exome sequenced (WES) CC cells lines and xenografts. METHODS: Olaparib cell-cycle, apoptosis, homologous-recombination-deficiency (HRD), PARP trapping and cytotoxicity activity was evaluated against 9 primary CC cell lines in vitro. PARP and PAR expression were analyzed by Western blot assays. Finally, olaparib in vivo antitumor activity was tested against CC xenografts. RESULTS: While none of the cell lines demonstrated HRD, three out of 9 (33.3%) primary CC cell lines showed strong PARylation activity and demonstrated high sensitivity to olaparib in vitro treatment (cutoff IC50 values < 2 μM, p = 0.0012). Olaparib suppressed CC cell growth through cell cycle arrest in the G2/M phase and caused apoptosis (p < 0.0001). Olaparib activity in CC involved both PARP enzyme inhibition and trapping. In vivo, olaparib significantly impaired CC xenografts tumor growth (p = 0.0017) and increased overall animal survival (p = 0.008). CONCLUSIONS: A subset of CC primary cell lines is highly responsive to olaparib treatment in vitro and in vivo. High level of PARylation correlated with olaparib preclinical activity and may represent a useful biomarker for the identification of CC patients benefitting the most from PARPi.
引用
- Bianchi A, Lopez S, Altwerger G, et al. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol Oncol. 2019. PMID: 31434613. doi:10.1016/j.ygyno.2019.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。